In the News

201 News Items found
Four people who were successfully treated for rectal cancer in a clinical trial at Memorial Sloan Kettering are seen posing outdoors with the trial’s two principal investigators.
Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.
Woman in field with dog dressed as tiger
MSK surgeons do an innovative procedure called a uterine transposition — the first performed in the U.S. — to preserve a woman’s fertility during cancer treatment.
MSK bile duct cancer patient Berta Pesantez
For many patients, time is of the essence. At MSK, patients have access to potentially lifesaving therapies long before they are available at community hospitals. Learn how MSK’s Cancer Health Equity Research Program (CHERP) partners with a network of public hospitals in New York City to recruit underserved patients for clinical trials at MSK and give them access to world-class care.
Dr. Debyani Chakravarty
Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate disparities in cancer outcomes.
Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to <i>U.S. News & World Report</i> in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago, MSK has held either the first or second spot each year for cancer care. MSK was also ranked first in gynecology.
MSK patient Dana Vergara smiles as she holds her baby Hudson.
Baby Hudson Makes History
Learn about Dana and the uterine transposition surgery at MSK in NYC, that enabled her to give birth to a baby named Hudson, who made history.
Bob Li, MD, PhD, MPH
Memorial Sloan Kettering’s Bob Li served as principal investigator of the CodeBreaK 100 trial, the largest clinical trial conducted to date exclusively for patients with the KRAS G12C mutation.
John Mendelsohn
Feature
The scientific world lost one of its greats this week. Here, we reflect on his influence.
A close up of a microscope with two people wearing white coats in the background
MSK highlights from the recent European Society for Medical Oncology (ESMO) Congress include promising findings on new lung, pancreatic, and colorectal cancer treatments and new insights for how molecular testing can guide personalized medicine.
MSK-IMPACT
Fifty years ago, the signing of the National Cancer Act ushered in a new era of cancer research and care.